Orexin Antagonism for Suicide Risk: A Proof-of-Concept Clinical Trial
NCT06854224
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
30
Enrollment
OTHER
Sponsor class
Conditions
Suicide Risk
Major Depressive Disorder (MDD)
Interventions
DRUG:
Suvorexant (dual orexin receptor antagonist)
Sponsor
Marianne Goodman
Collaborators
[object Object]